Tarsus Pharmaceuticals, Inc.

What they do

Tarsus received FDA approval in July 2023 for XDEMVY (lotilaner ophthalmic solution) 0.25%, the first and only approved therapeutic for Demodex blepharitis, a mite-caused eyelid inflammation affecting as many as approximately 25 million people in the U.S. The company launched XDEMVY in August 2023 and commercializes it through eye care professionals. It also develops lotilaner-based candidates: TP-04 for ocular rosacea, TP-05 oral tablets for Lyme disease prophylaxis, and, through acquisitions, IRX-101 for intravitreal injection tolerability and ALK-001 for Stargardt disease.

Revenue drivers

• XDEMVY net product sales — Essentially all revenue comes from U.S. sales of XDEMVY for Demodex blepharitis; second quarter 2026 net product sales were $173.9 million, up more than 69% year-over-year.
• Gross-to-net improvement and volume — Q2 2026 growth versus $102.7 million in the prior-year period was driven by higher volume and improvements in gross-to-net deductions per the earnings release.
• Prescriber depth and DTC promotion — The number of eye care professionals prescribing XDEMVY five or more times per week doubled year-over-year, supported by direct-to-consumer campaigns.

Recent performance

Second quarter 2026 XDEMVY net product sales were $173.9 million versus $102.7 million in the same period in 2025, an increase of more than 69%. Quarterly revenue has risen sequentially from $118.7 million in Q3 2025 to $151.7 million in Q4 2025 and $162.1 million in Q1 2026. Full-year 2025 revenue was $451.4 million with a net loss of $66.0 million, compared with a $116.0 million net loss on $183.0 million of revenue in 2024. At June 30, 2026, cash and equivalents were $204.6 million against total liabilities of $264.4 million. Operating cash flow was negative $12.5 million for 2025, a substantial narrowing from negative $83.0 million in 2024.

Strategy

Management raised full-year 2026 XDEMVY net product sales guidance to $685-705 million while continuing DTC promotion, including a celebrity campaign with John Cena and an unbranded television campaign. Tarsus completed the acquisition of iRenix Medical, adding IRX-101, an investigational ocular antiseptic for intravitreal injections, and plans a Phase 3 COMFORT trial in the first half of 2027. It entered an agreement to acquire Alkeus Pharmaceuticals and ALK-001, an oral therapy for Stargardt disease with a Phase 3 program, and priced a $125 million private placement. Near-term pipeline catalysts include Phase 2 topline data for TP-04 in ocular rosacea and TP-05 in Lyme disease prophylaxis, both expected in the first half of 2027. These moves are intended to build a multi-product eye care company beyond a single commercial asset.

Risks

• Single approved product — The company has one FDA-approved product, XDEMVY, so any decline in its sales, demand, or payer coverage would directly reduce revenue.
• History of losses and negative cash flow — Tarsus has incurred net losses every year since formation in 2016, including $66.4 million in 2025, $115.6 million in 2024, and $135.9 million in 2023, and has had negative operating cash flow.
• Pipeline and clinical timing risk — TP-04, TP-05, IRX-101, and ALK-001 are investigational, and their trials may not demonstrate safety or efficacy or meet stated timelines.
• Acquisition integration risk — The pending Alkeus acquisition and completed iRenix acquisition carry integration and benefit-realization risks that management identifies as forward-looking uncertainties.

Outlook

Management guided full-year 2026 XDEMVY net product sales to $685-705 million after raising its prior range. Topline data for the Phase 2 KORE trial of TP-04 in ocular rosacea and for the Phase 2 Calliope trial of TP-05 in Lyme disease prophylaxis are both expected in the first half of 2027. The Phase 3 COMFORT trial of IRX-101 is anticipated to begin in the first half of 2027 with topline results expected in 2028. Closing and integration of the pending Alkeus acquisition would add a Phase 3 retina program for Stargardt disease.